Zantac Injection (Ranitidine Hydrochloride Injection) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Zantac Injection

Gastroesophageal Reflux Disease (GERD) »

GERD Facts

GERD is a condition in which the acidified liquid content of the stomach up into the esophagus.
The causes of GERD include an abnormal lower esophageal sphincter, hiatal hernia, abnormal esophageal contractions, and slow emptying of the stomach.
GERD may damage the lining of the esophagus, thereby causing inflammation (esophagitis), although usually it does not.
The symptoms of uncomplicated GERD are heartburn, regurgitation, and nausea.
Complications of GERD include ulcers and strictures of the esophagus, Barrett's esophagus, cough and asthma, throat and laryngeal inflammation, inflammation and infection of the lungs, and collection of fluid in the sinuses and middle ear.
Barrett's esophagus is a pre-cancerous condition that requires periodic endoscopic surveillance for the development of cancer.
GERD may be diagnosed or evaluate...

Read the Gastroesophageal Reflux Disease (GERD) article »

Zantac Injection

Heartburn: Foods to Eat, Foods to Avoid Slideshow Pictures

Digestive Disease Myths Slideshow Pictures

Diverticulitis (Diverticulosis) Slideshow Pictures

font size

ZANTAC®
(ranitidine hydrochloride) Injection

ZANTAC®
(ranitidine hydrochloride) Injection Premixed

DRUG DESCRIPTION

The active ingredient in ZANTAC Injection and ZANTAC Injection Premixed is ranitidine hydrochloride (HCl), a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, hydrochloride. It has the following structure:

ZANTAC® (ranitidine hydrochloride) Structural Formula Illustration

The empirical formula is C₁₃H₂₂N₄O₃S•HCl, representing a molecular weight of 350.87.

Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water.

ZANTAC Injection (ranitidine hydrochloride injection) is a clear, colorless to yellow, nonpyrogenic liquid. The yellow color of the liquid tends to intensify without adversely affecting potency. The pH of the injection solution is 6.7 to 7.3.

Sterile Injection for Intramuscular or Intravenous Administration

Each 1 mL of aqueous solution contains ranitidine 25 mg (as the hydrochloride); phenol 5 mg as preservative; and 0.96 mg of monobasic potassium phosphate and 2.4 mg of dibasic sodium phosphate as buffers.

Sterile, Premixed Solution for Intravenous Administration in Single-Dose, Flexible Plastic Containers

Each 50 mL contains ranitidine HCl equivalent to 50 mg of ranitidine, sodium chloride 225 mg, and citric acid 15 mg and dibasic sodium phosphate 90 mg as buffers in water for injection. It contains no preservatives. The osmolarity of this solution is 180 mOsm/L (approx.), and the pH is 6.7 to 7.3.

The flexible plastic container is fabricated from a specially formulated, nonplasticized, thermoplastic co-polyester (CR3). Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions inside the plastic container also can leach out certain of the chemical components in very small amounts before the expiration period is attained. However, the safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers.

Last reviewed on RxList: 3/30/2009
This monograph has been modified to include the generic and brand name in many instances.